Clinical Trial Update: A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) [Phase 2]

View source ↗

Summary

Phase 2 diagnostic imaging trial evaluating copper-64 SARTATE for PET imaging in patients with known or suspected neuroendocrine tumors has completed. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• 64Cu-SARTATE (Copper-64 SARTATE)

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED